Scarica l'app Stockscreener
48.51
3.88%
1.8049
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$46.71
Aprire:
$47.105
Volume 24 ore:
1.96M
Relative Volume:
0.25
Capitalizzazione di mercato:
$19.26B
Reddito:
$2.23B
Utile/perdita netta:
$-3.19B
Rapporto P/E:
-5.9555
EPS:
-8.1462
Flusso di cassa netto:
$-1.60B
1 W Prestazione:
+6.13%
1M Prestazione:
-0.51%
6M Prestazione:
+99.44%
1 anno Prestazione:
+98.62%
Intervallo 1D:
$46.73
$48.69
Intervallo di 1 settimana:
$43.68
$48.69
Portata 52W:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
48.53 | 18.53B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
425.29 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
720.65 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.77 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.21 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.86 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna stands as the best performing large-cap healthcare stock YTD - MSN
FDA halts publication of studies on COVID, shingles vaccines - Seeking Alpha
Brookline Capital Markets Weighs in on Moderna Q2 Earnings - MarketBeat
Non-covid mRNA Vaccine and Therapeutics Market Supply Chain Analysis and Revenue Forecast 2026 to 2035 - openPR.com
Moderna (MRNA) Receives a Buy from Piper Sandler - The Globe and Mail
Sigma Planning Corp Makes New $907,000 Investment in Moderna, Inc. $MRNA - MarketBeat
Abbas Hussain Sells 5,682 Shares of Moderna (NASDAQ:MRNA) Stock - MarketBeat
Moderna director Abbas sells $264,951 in shares - Investing.com
Sandra Horning at Moderna (NASDAQ: MRNA) gains 16,233 shares via RSU vesting - Stock Titan
Director Rubenstein acquires 8,116 Moderna (NASDAQ: MRNA) shares - Stock Titan
Tax-driven stock sale by Moderna (MRNA) director after RSU vesting - Stock Titan
Director at Moderna (MRNA) receives 16,233 shares as RSUs vest - Stock Titan
Director at Moderna (NASDAQ: MRNA) receives 12,174 vested shares - Stock Titan
MRNA Maintained by RBC Capital -- Price Target Raised to $38.00 - GuruFocus
Moderna (MRNA) director converts 4,058 RSUs into common stock - Stock Titan
Moderna shares rise as investors revisit Q1 results, pipeline milestones, and fresh price-target bumps - Quiver Quantitative
Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era - Yahoo Finance
UBS Adjusts Price Target on Moderna to $45 From $36, Maintains Neutral Rating - marketscreener.com
Mitsubishi UFJ Trust & Banking Corp Boosts Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
The Zacks Analyst Blog Highlights Moderna, Merck and Vertex Pharmaceuticals - The Globe and Mail
Brokers Issue Forecasts for Moderna FY2029 Earnings - MarketBeat
MRNA Q1 Deep Dive: International Partnerships and Pipeline Progress Offset Litigation Headwinds - Yahoo Finance
Moderna’s Stock Rises in 2026 as International COVID-19 Vaccine Sales Offset U.S. Decline - geneonline.com
Moderna’s strong vaccine sales outside US far surpass estimates - The Boston Globe
Moderna (MRNA) Is Down 10.6% After Q1 Loss Widened On Settlement And EU Vaccine Wins – Has The Bull Case Changed? - Yahoo Finance
ProShares Ultra S&P 500 Equal Weight's Moderna Inc(MRNA) Holding History - GuruFocus
Vanguard Group Inc. Purchases 399,487 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Q1 2026 Earnings Call Transcript - Insider Monkey
A Look At Moderna (MRNA) Valuation After Q1 2026 Earnings And New Vaccine Approvals - Yahoo Finance
Moderna Inc (MRNA) Q1 2026 Earnings Call Highlights: Strategic Growth Amidst Legal Challenges By GuruFocus - Investing.com Canada
Moderna Inc (MRNA) Q1 2026 Earnings Call Highlights: Strategic Growth Amidst Legal Challenges - GuruFocus
Moderna (MRNA) Reports Strong Q1 2026 Performance with $400 Million Revenue - GuruFocus
Research Alert: CFRA Maintains Hold Rating On Shares Of Moderna, Inc. After Q1 Earnings - Moomoo
Moderna, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Legal settlement drives Q1 2026 loss at Moderna (NASDAQ: MRNA) - Stock Titan
Moderna, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Moderna first-quarter revenue jumps on strong overseas COVID vaccine sales - The Economic Times
Moderna’s Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. - Barron's
Sector Update: Health Care Stocks Softer Friday Afternoon - Moomoo
Moderna, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:MRNA) 2026-05-01 - Seeking Alpha
Moderna’s first quarter 2026 sales well ahead of estimates - The Pharma Letter
RBC Capital raises Moderna stock price target on Q1 beat - Investing.com
RBC Capital raises Moderna stock price target on Q1 beat By Investing.com - Investing.com Canada
Biotech Stocks To Follow TodayMay 1st - MarketBeat
Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales - The Globe and Mail
Moderna sees revenue bump from international COVID vaccine sales - BioPharma Dive
Moderna reports mixed Q1 results as revenue beats estimates but litigation charge weighs on earnings - Yahoo! Finance Canada
[144] Moderna, Inc. SEC Filing - Stock Titan
BofA raises Moderna stock price target to $32 on Q1 beat - Investing.com
Moderna Sales Triple To $389 Million As Shares Rise 5.4% - GuruFocus
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):